October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior’s clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.

“Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior,” said Elizabeth G. Trehu, MD, FACP, Promedior’s Chief Medical Officer. “We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151’s novel mechanism of action is applicable to a wide range of fibrotic diseases.”


Read the entire article at:


For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

This entry was posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

One Response to October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

  1. extreme rush says:

    Hello there! Quick question that’s entirely off topic.
    Do you know how to make your site mobile friendly? My site
    looks weird when viewing from my apple iphone. I’m trying to find a theme or plugin that
    might be able to resolve this problem. If you have any recommendations, please share.
    Many thanks!

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>